BOCCACCINO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 603
EU - Europa 357
AS - Asia 164
AF - Africa 32
SA - Sud America 2
Totale 1.158
Nazione #
US - Stati Uniti d'America 598
IT - Italia 201
SG - Singapore 89
SE - Svezia 55
CN - Cina 49
BG - Bulgaria 25
DE - Germania 24
GB - Regno Unito 24
CI - Costa d'Avorio 20
VN - Vietnam 10
PL - Polonia 9
FR - Francia 7
NG - Nigeria 7
HK - Hong Kong 6
CA - Canada 5
TR - Turchia 5
SN - Senegal 4
ES - Italia 3
FI - Finlandia 3
RU - Federazione Russa 3
IN - India 2
AT - Austria 1
CL - Cile 1
CO - Colombia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
IL - Israele 1
KH - Cambogia 1
MY - Malesia 1
UA - Ucraina 1
Totale 1.158
Città #
Chandler 76
Fairfield 67
Singapore 45
Florence 42
Ashburn 38
Wilmington 37
New York 34
Seattle 32
Santa Clara 29
Boardman 28
Cambridge 27
Pisa 26
Sofia 25
Woodbridge 22
Abidjan 20
London 16
Princeton 16
Lawrence 15
Ogden 14
Genoa 13
Bremen 12
Medford 12
Serra 10
Rome 9
Warsaw 9
Ann Arbor 8
Houston 8
Lagos 7
Los Angeles 7
Munich 7
Milan 6
Quanzhou 6
San Diego 6
Shanghai 6
Turin 6
Verona 6
Istanbul 5
Kent 5
Seacroft 5
Beijing 4
Dakar 4
Fuzhou 4
Hong Kong 4
Phoenix 4
Polverigi 4
Redwood City 4
Dallas 3
Gargallo 3
Helsinki 3
Pistoia 3
Washington 3
Anzio 2
Bari 2
Cesano Boscone 2
Clifton 2
Des Moines 2
Dong Ket 2
Fano 2
Marina di Ravenna 2
Moscow 2
Nanchang 2
Nanjing 2
Norwalk 2
Noventa di Piave 2
Ottawa 2
San Giuliano Terme 2
Santa Maria A Monte 2
Toronto 2
Vitry-sur-seine 2
Barcelona 1
Bellinzago Novarese 1
Berlin 1
Berlingo 1
Buffalo 1
Cairo 1
Castiglione Chiavarese 1
Catania 1
Central 1
Città della Pieve 1
Cologne 1
Council Bluffs 1
Dearborn 1
Fiumefreddo Di Sicilia 1
Fort Worth 1
Frankfurt am Main 1
Frattamaggiore 1
Guangzhou 1
Hanoi 1
Hebei 1
Indore 1
Kowloon 1
Kuala Lumpur 1
Kunming 1
Kyiv 1
Marseille 1
Montefalco 1
Nagold 1
Nanning 1
Perugia 1
Phnom Penh 1
Totale 872
Nome #
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 111
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 101
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 92
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 75
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 73
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 68
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 62
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 52
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 49
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 49
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 45
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 44
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 43
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 43
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 40
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 37
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 35
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 31
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 27
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 25
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 22
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 21
null 15
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 14
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 12
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 11
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 7
Totale 1.204
Categoria #
all - tutte 5.952
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.952


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020103 0 0 0 0 21 16 18 15 14 9 9 1
2020/2021117 3 2 3 6 1 42 2 6 13 5 12 22
2021/2022124 1 0 2 0 17 23 2 5 4 16 15 39
2022/2023320 23 47 19 23 30 31 17 20 51 2 48 9
2023/2024282 11 24 36 32 32 37 16 14 5 13 38 24
2024/2025195 35 40 28 58 34 0 0 0 0 0 0 0
Totale 1.204